Sawgrass Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM
Sawgrass Asset Management's ALXN Position: Q3 2021 in Review
Sawgrass Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,573 shares — an estimated $473K sold.
Sawgrass Asset Management first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $12.5M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.
- Sawgrass Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
- Sawgrass Asset Management sold 2,573 Alexion Pharmaceuticals shares in Q3 2021, an estimated $473K.
- Sawgrass Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
- Sawgrass Asset Management's Alexion Pharmaceuticals position peaked at $12.5M in Q4 2020.
- 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.
Based on Sawgrass Asset Management's 13F filing for Q3 2021, filed 4 Nov 2021.